Le Lézard
Classified in: Health, Business
Subject: LIC

Caldic Announces A Strategic Partnership With Celesta To Bring Sleep And Stress Reduction Ingredient Blends To The USA and Canada


Caldic has entered into a strategic partnership with Celesta, a leading formulator of science-based stress reduction and sleep-promoting ingredients.

MISSISSAUGA, ON , March 12, 2024 /PRNewswire-PRWeb/ -- Caldic North America has announced a strategic partnership with Celesta Company LLC, a leading formulator of science-based stress reduction and sleep-promoting ingredient blends. This collaboration will further expand Caldic's portfolio through the introduction of Celesta's proprietary ingredient blends and technologies designed to enhance sleep, mood, and relaxation, including the SlumberMortm and RnRMortm. This new offering will enable the delivery of value-added solutions and help drive innovation in the food, beverage, snack, and pet food industry. Caif Nutrition ? the division of Caldic North America specializing in functional and nutritional ingredients ? will market the complementary portfolio in the United States and Canada.

"Caldic is pleased to partner with Celesta in bringing these scientifically substantiated products to the market and we look forward to working with our customers to formulate outstanding products that deliver the important benefits found in SlumberMortm and RnRMortm to the consumer."

"We are excited to enter into this partnership with the talented team at Caldic", said Dave Lafond, Celesta CEO. "Our strong scientific research focus combined with our joint product know-how and formulation capabilities provide a solid foundation to develop new opportunities that address the ever-increasing demand for products that lower stress levels and positively contribute to mental health."

"Research proves that relaxation and sleep are critical components to one's overall health and wellness and consumers are searching for effective products", said Nick Bruns, Commercial Head for Nutrition of Caldic North America. "Caldic is pleased to partner with Celesta in bringing these scientifically substantiated products to the market and we look forward to working with?our customers to formulate outstanding products that deliver the important benefits found in SlumberMortm and RnRMortm to the consumer."

Celesta has developed proprietary herbal ingredient blends that target well-being, addressing in particular sleep induction, sleep duration, stress reduction, body recovery, and mood stabilization. These blends are scientifically proven and formulated to enhance CPG beverages, powder mixes, capsules, gummies and pet foods. They include SlumberMortm, which significantly improves sleep quality and subsequently overall quality of living and RnRMortm, that helps reduce stress, increase focus, and encourages rest and relaxation, aiding every facet of our day-to-day lives.

About Celesta:

Celesta, a women-owned company, is on a mission to improve sleep, relaxation, and the ways we think about both, through the launch of patent-pending, ingredient blends. Targeting stress reduction, Celesta formulated a combination of clinically researched ingredients that act together to reduce stress, promote calmness, and enhance focus, under the brand RnRMortm. The SlumberMortm brand was formulated to address the length of time to fall asleep, sleep quality, and sleep duration. Armed with global patent-pending formulations, we are committed to helping people live better lives through quality relaxation and sleep. In support of this mission, we're also in the process of establishing the Relaxation and Sleep Science Institute (RSSI) to be a premier knowledge center for consumers to find credible information on the science supporting relaxation and sleep.

For more information, please visit https://www.celestaco.com/

About Caldic:

"Because we care", we touch the lives of hundreds of thousands of people every day. We inspire innovative and sustainable solutions in life science and material science for the food, pharmaceutical, personal care, and industrial formulation markets around the world. Our solutions, carefully sourced and customized to exacting specifications whenever required, are backed by research & development, customer service, technical & regulatory support, ensuring that they meet precisely determined needs at every stage of the value chain.

Across Europe, Latin America, North America and Asia Pacific, our approximately 4,000 employees go the extra mile, day in and day out, to deliver value-added solutions to our customers. In our activities, we embrace the principles of sustainability, designing products, services, and processes with these principles in mind. From formulation to delivery, from ingredient to packing, from supplier to customer, we care about every detail of what we do. Because every detail is in our care.

For more information, please visit www.caldic.com

Join us at Natural Products Expo West Anaheim, California, from March 12-16th at Booth 3381, to witness the exciting joint launch of Celesta's RnRMortm and SlumberMortm, the latest additions to Caldic's premium portfolio of health and wellness ingredients and blends for the food, beverage, and nutrition market.

Media Contact

Zane Hussein, Caldic North America, 1 4168993788, [email protected], www.caldic.com

SOURCE Caldic North America


These press releases may also interest you

at 08:15
Masimo Corporation ("Masimo" or the "Company") today issued a letter to stockholders in connection with the Company's 2024 Annual Meeting of Stockholders. The letter highlights the fierce independence and deep medtech experience of nominee...

at 08:15
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced that the FDA has cleared the Investigational New Drug (IND) application for the STEALTH-001 study...

at 08:10
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited...

at 08:10
Kashiv BioSciences, LLC ("Kashiv" or the "Company") today announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR®, with Amneal Pharmaceuticals, Inc. ("Amneal") for the...

at 08:10
N-Power Medicine, a company reinventing the clinical trial process, announced the initial close of a Series B funding round, raising its total funding to date to $72 Million. The Series B round is led by Merck Global Health Innovation Fund, with...

at 08:07
NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company posted a new Shareholder Update Letter on its website NRx Shareholder Update and further invites...



News published on and distributed by: